May 15 is #TSGlobalDay, the day on which the international Tuberous Sclerosis Community shares information and their stories about TSC to raise awareness of this condition, which affects an estimated 1 million people worldwide. Here are 15 facts about TSC which give the basics about
At the TSA we try to give everyone who engages with us an experience where they feel valued and supported. This includes people living with TSC, their families and carers as well as all of our amazing fundraisers and volunteers.  We have therefore decided to
The TSA is really pleased to hear of such positive results from a recent trial of topical rapamycin for the treatment of facial angiofibromas. The study, which took place in America and Australia and more details of which you can find on the link below,
A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of Cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with Tuberous Sclerosis Complex who experience inadequately-controlled seizures NCT02544763 How long is the study? Study length: 5 weeks of baseline and 16 weeks of treatment
